Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation

Bone Marrow Transplant. 2016 Jul;51(7):999-1001. doi: 10.1038/bmt.2016.28. Epub 2016 Mar 7.

Authors

A Varma^{1

2}, R M Saliba², H A Torres³, A Afrough², C Hosing², I F Khouri², Y Nieto², N D Shah², S Parmar², Q Bashir², S Ahmed², R B Jones², P Kebriaei², A L Olson², E J Shpall², A M Alousi², M H Qazilbash², R E Champlin², U Popat²

Affiliations

¹ Department of Hematology-Oncology, Baylor College of Medicine, Houston, TX, USA.
² Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

No abstract available

MeSH terms

Aged
Female
Hematopoietic Stem Cell Transplantation / adverse effects
Hepacivirus
Hepatitis C / blood
Hepatitis C / therapy*
Humans
Lymphoma / blood
Lymphoma / therapy*
Lymphoma / virology*
Male
Middle Aged
Multiple Myeloma / blood
Multiple Myeloma / therapy*
Multiple Myeloma / virology*
Prevalence
Proportional Hazards Models
Retrospective Studies
Risk Factors
Stem Cell Transplantation
Survival Rate
Transplantation, Autologous
Treatment Outcome
Viral Load

Grants and funding

P30 CA016672/CA/NCI NIH HHS/United States